Literature DB >> 32258651

Cardiac effects of Ledipasvir plus sofosbuvir for Hepatitis C treatment in thalassemia: PS067.

H Karimi-Sari1,2,3,4, A Khosravi1,2,3,4, B Behnava1,2,3,4, M Abedi-Andani1,2,3,4, S M Alavian1,2,3,4.   

Abstract

Entities:  

Year:  2017        PMID： 32258651      PMCID： PMC6806804          DOI： 10.1016/j.pbj.2017.07.039

Source DB:  PubMed          Journal:  Porto Biomed J        ISSN： 2444-8664


× No keyword cloud information.
  3 in total

1.  Outcome of Combination Therapy with Sofosbuvir and Ledipasvir for Chronic Type C Liver Disease.

Authors:  Satoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Toshiharu Sakurai; Hiroshi Ida; Yasunori Minami; Masahiro Takita; Tomohiro Minami; Mina Iwanishi; Hirokazu Chishina; Kazuomi Ueshima; Yoriaki Komeda; Tadaaki Arizumi; Masatoshi Kudo
Journal:  Oncology       Date:  2016-12-15       Impact factor: 2.935

2.  High incidence of cardiac dysfunction and response to antiviral treatment in patients with chronic hepatitis C virus infection.

Authors:  Wolfgang Poller; Ziya Kaya; Marion Muche; Mario Kasner; Carsten Skurk; Kai Kappert; Rudolf Tauber; Felicitas Escher; Heinz-Peter Schultheiss; Hans-Jörg Epple; Ulf Landmesser
Journal:  Clin Res Cardiol       Date:  2017-02-24       Impact factor: 5.460

3.  Trend in Prevalence of Hepatitis C Virus Infection among β-thalassemia Major Patients: 10 Years of Experience in Iran.

Authors:  Maryam Jafroodi; Ali Davoudi-Kiakalayeh; Zahra Mohtasham-Amiri; Ali Akbar Pourfathollah; Azade Haghbin
Journal:  Int J Prev Med       Date:  2015-09-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.